SCHEMBL1168411

SCHEMBL1168411

Cc1ccc(Cl)c(CO)c1F

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 3/20 0.43
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
HTR2B P41595 1/20 0.39
TAAR1 Q96RJ0 1/20 0.34
NOTUM Q6P988 1/20 0.33
RORC P51449 1/20 0.33
S1PR1 P21453 4/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
GAA P10253 1/20 0.32
PKM P14618 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
ADRA2A P08913 1/20 0.30
CLCN2 P51788 1/20 0.30
CYP3A4 P08684 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15787544 0.82 P2RX7 (0.40) P2RX7HTR2AHTR2CHTR2BTAAR1
SCHEMBL17414242 0.82 TAAR1 (0.39) P2RX7TAAR1NOTUMGAASMN1; SMN2
SCHEMBL9608985 0.81 P2RX7 (0.40) P2RX7HTR2AHTR2CHTR2BTAAR1
SCHEMBL955817 0.79 HTR2A (0.42) P2RX7HTR2AHTR2CHTR2BTAAR1
SCHEMBL3591836 0.79 HTR2A (0.46) P2RX7HTR2AHTR2CHTR2BTAAR1
SCHEMBL25374465 0.78 NOTUM (0.42) NOTUMS1PR1ALDH1A1LMNAGAA
SCHEMBL20534630 0.78 TAAR1 (0.41) TAAR1NOTUMRORCALDH1A1GAA
SCHEMBL29970924 0.78 TAAR1 (0.41) TAAR1NOTUMRORCALDH1A1GAA
SCHEMBL1166843 0.78 ENPP2 (0.33) P2RX7
SCHEMBL3742494 0.77 AKR1B1 (0.53) P2RX7RORCGAAADRA2ACLCN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2242743-B1 AMINOPYRAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2013-08-21 EP disclosed
CN-101903353-B Aminopyrazole derivatives ACTELION PHARMACEUTICALS LTD 2013-04-10 CN disclosed
US-8288419-B2 Aminopyrazole derivatives ACTELION PHARMACEUTICALS, LTD (CH) 2012-10-16 US disclosed
US-20110034516-A1 AMINOPYRAZOLE DERIVATIVES ACTELION (CH) 2011-02-10 US disclosed
CN-101903353-A Aminopyrazole derivatives ACTELION PHARMACEUTICALS LTD 2010-12-01 CN disclosed
EP-2242743-A1 AMINOPYRAZOLE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-10-27 EP disclosed
WO-2009077954-A1 AMINOPYRAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-06-25 WO disclosed
US-20090131502-A1 Biologically active compounds QUIBELL MARTIN 2009-05-21 US disclosed
WO-2007023281-A2 BIOLOGICALLY ACTIVE COMPOUNDS AMURA THERAPEUTICS LIMITED (GB) 2007-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034516-A1 AMINOPYRAZOLE DERIVATIVES CYP3A43, CYP1A2, CYP3A5 P2RX7 343/4885HTR2A 1210/4885HTR2C 885/4885
US-20090131502-A1 Biologically active compounds COLGALT1, SOST, COL1A1 P2RX7 1404/4885HTR2A 4611/4885HTR2C 4708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.